H5N1 influenza virus-like particle vaccine protects mice from heterologous virus challenge better than whole inactivated virus

Virus Research

Volumn 200, Issue C, 2015, Pages 9-18

  Ren, Zhiguang ^a,b   Ji, Xianliang ^b,c   Meng, Lingnan ^b,d   Wei, Yurong ^b,e   Wang, Tiecheng ^b   Feng, Na ^b   Zheng, Xuexing ^b   Wang, Hualei ^b   Li, Nan ^b   Gao, Xiaolong ^b   Jin, Hongli ^f   Zhao, Yongkun ^b   Yang, Songtao ^b   Qin, Chuan ^a   Gao, Yuwei ^b,g,h   Xia, Xianzhu ^a,b,g,h  

^a INSTITUTE OF LABORATORY ANIMAL SCIENCE   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c INNER MONGOLIA AGRICULTURAL UNIVERSITY   (China)

^d JILIN AGRICULTURAL UNIVERSITY   (China)

^e SHIHEZI UNIVERSITY   (China)

^f Changchun Biological Technology Co Ltd   (China)

^g YANGZHOU UNIVERSITY   (China)

^h INSTITUTE OF PLANT PROTECTION   (China)

Author keywords

Cross protective; H5N1 influenza; Protection; Vaccine; Virus like particles

Indexed keywords

AVIAN INFLUENZA VACCINE; H5N1 INFLUENZA VIRUS LIKE PARTICLE VACCINE; HEMAGGLUTININ; INACTIVATED VIRUS VACCINE; SIALIDASE; UNCLASSIFIED DRUG; INFLUENZA VACCINE; VIRUS ANTIBODY; VIRUS LIKE PARTICLE VACCINE;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; VACCINATION; VIRUS LIKE AGENT; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; BAGG ALBINO MOUSE; CHICK EMBRYO; CLASSIFICATION; CROSS PROTECTION; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; INFLUENZA A VIRUS; INFLUENZA A VIRUS (H5N1); INFLUENZA, HUMAN; VIROLOGY;

AVES; MUS; ORTHOMYXOVIRIDAE;

ANIMALS; ANTIBODIES, VIRAL; CHICK EMBRYO; CROSS PROTECTION; FEMALE; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84927509908     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2015.01.007     Document Type: Article

References (47)

1. Abe T., Hemmi H., Miyamoto H., Moriishi K., Tamura S., Takaku H., Akira S., Matsuura Y. Involvement of the toll-like receptor 9 signaling pathway in the induction of innate immunity by baculovirus. J. Virol. 2005, 79:2847-2858.
2. Abe T., Kaname Y., Wen X.Y., Tani H., Moriishi K., Uematsu S., Takeuchi O., Ishii K.J., Kawai T., Akira S., Matsuura Y. Baculovirus induces Type I interferon production through Toll-like receptor-dependent and -independent pathways in a cell-type-specific manner. J. Virol. 2009, 83:7629-7640.
3. Banzhoff A., Gasparini R., Laghi-Pasini F., Staniscia T., Durando P., Montomoli E., Capecchi P.L., di Giovanni P., Sticchi L., Gentile C., Hilbert A., Brauer V., Tilman S., Podda A. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PloS One 2009, 4:e4384.
4. Barrett P.N., Portsmouth D., Ehrlich H.J. Developing cell culture-derived pandemic vaccines. Curr. Opin. Mol. Therap. 2010, 12:21-30.
5. Bower J.F., Green T.D., Ross T.M. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1. Virology 2004, 328:292-300.
6. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., Hoschler K., Zambon M.C. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006, 367:1657-1664.
7. Bright R.A., Carter D.M., Crevar C.J., Toapanta F.R., Steckbeck J.D., Cole K.S., Kumar N.M., Pushko P., Smith G., Tumpey T.M., Ross T.M. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PloS One 2008, 3:e1501.
8. Bright R.A., Carter D.M., Daniluk S., Toapanta F.R., Ahmad A., Gavrilov V., Massare M., Pushko P., Mytle N., Rowe T., Smith G., Ross T.M. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007, 25:3871-3878.
9. Choi J.G., Kang H.M., Jeon W.J., Choi K.S., Kim K.I., Song B.M., Lee H.S., Kim J.H., Lee Y.J. Characterization of clade 2.3.2.1 H5N1 highly pathogenic avian influenza viruses isolated from wild birds (mandarin duck and Eurasian eagle owl) in 2010 in Korea. Viruses 2013, 5:1153-1174.
10. Choi J.G., Kim M.C., Kang H.M., Kim K.I., Lee K.J., Park C.K., Kwon J.H., Kim J.H., Lee Y.J. Protective efficacy of baculovirus-derived influenza virus-like particles bearing H5 HA alone or in combination with M1 in chickens. Vet. Microbial. 2013, 162:623-630.
11. Erlewyn-Lajeunesse M., Brathwaite N., Lucas J.S.A., Warner J.O. Recommendations for the administration of influenza vaccine in children allergic to egg. BMJ 2009, 339. 10.1136/bmj.b3680.
12. Fan S., Zhou L., Wu D., Gao X., Pei E., Wang T., Gao Y., Xia X. A novel highly pathogenic H5N8 avian influenza virus isolated from a wild duck in China. Influenza Other Respir. Viruses 2014, 8:646-653.
13. Ferguson N.M., Cummings D.A., Fraser C., Cajka J.C., Cooley P.C., Burke D.S. Strategies for mitigating an influenza pandemic. Nature 2006, 442:448-452.
14. Geeraedts F., Bungener L., Pool J., ter Veer W., Wilschut J., Huckriede A. Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs. Influenza Other Respir. Viruses 2008, 2:41-51.
15. Gessner J.E., Heiken H., Tamm A., Schmidt R.E. The IgG Fc receptor family. Ann. Hematol. 1998, 76:231-248.
16. Hervas-Stubbs S., Rueda P., Lopez L., Leclerc C. Insect baculoviruses strongly potentiate adaptive immune responses by inducing type I IFN. J. Immunol. 2007, 178:6653.
17. Heusser C.H., Anderson C.L., Grey H.M. Receptors for IgG: subclass specificity of receptors on different mouse cell types and the definition of two distinct receptors on a macrophage cell line. J. Exp. Med. 1977, 145:1316-1327.
18. Hobson D., Curry R.L., Beare A.S., Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg. 1972, 70:767-777.
19. Huber V.C., McKeon R.M., Brackin M.N., Miller L.A., Keating R., Brown S.A., Makarova N., Perez D.R., Macdonald G.H., McCullers J.A. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin. Vaccine Immunol. 2006, 13:981-990.
20. Inn K.S., Lee G.J., Quan F.S. A pandemic H1N1 influenza virus-like particle vaccine induces cross-protection in mice. Immunol. Invest. 2014, 43:236-254.
21. Jin R., Lv Z., Chen Q., Quan Y., Zhang H., Li S., Chen G., Zheng Q., Jin L., Wu X., Chen J., Zhang Y. Safety and immunogenicity of H5N1 influenza vaccine based on baculovirus surface display system of Bombyx mori. PloS One 2008, 3:e3933.
22. Kang S.M., Yoo D.G., Kim M.C., Song J.M., Park M.K., Eunju O., Quan F.S., Akira S., Compans R.W. MyD88 plays an essential role in inducing B cells capable of differentiating into antibody-secreting cells after vaccination. J. Virol. 2011, 85:11391-11400.
23. Krammer F., Grabherr R. Alternative influenza vaccines made by insect cells. Trends Mol. Med. 2010, 16:313-320.
24. Krammer F., Schinko T., Palmberger D., Tauer C., Messner P., Grabherr R. Trichoplusia ni cells (High Five(TM)) are highly efficient for the production of influenza A virus-like particles: a comparison of two insect cell lines as production platforms for influenza vaccines. Mol. Biotechnol. 2010, 45:226-234.
25. Le T.H., Nguyen N.T. Evolutionary dynamics of highly pathogenic avian influenza A/H5N1 HA clades and vaccine implementation in Vietnam. Clin. Exp. Vaccine Res. 2014, 3:117-127.
26. Lee Y.J., Kang H.M., Lee E.K., Song B.M., Jeong J., Kwon Y.K., Kim H.R., Lee K.J., Hong M.S., Jang I., Choi K.S., Kim J.Y., Lee H.J., Kang M.S., Jeong O.M., Baek J.H., Joo Y.S., Park Y.H., Lee H.S. Novel Reassortant Influenza A(H5N8) Viruses, South Korea. Emerg. Infect. Dis. 2014, 20:1087-1089.
27. Lopez-Macias C., Ferat-Osorio E., Tenorio-Calvo A., Isibasi A., Talavera J., Arteaga-Ruiz O., Arriaga-Pizano L., Hickman S.P., Allende M., Lenhard K., Pincus S., Connolly K., Raghunandan R., Smith G., Glenn G. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine 2011, 29:7826-7834.
28. Ma J., Wang H., Zheng X., Xue X., Wang B., Wu H., Zhang K., Fan S., Wang T., Li N., Zhao Y., Gao Y., Yang S., Xia X. CpG/Poly (I:C) mixed adjuvant priming enhances the immunogenicity of a DNA vaccine against eastern equine encephalitis virus in mice. Int. Immunopharmacol. 2014, 19:74-80.
29. Margine I., Martinez-Gil L., Chou Y.Y., Krammer F. Residual Baculovirus in insect cell-derived influenza virus-like particle preparations enhances immunogenicity. PloS One 2012, 7:e51559.
30. Nicholson K.G., Colegate A.E., Podda A., Stephenson I., Wood J., Ypma E., Zambon M.C. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001, 357:1937-1943.
31. Perrone L.A., Ahmad A., Veguilla V., Lu X., Smith G., Katz J.M., Pushko P., Tumpey T.M. Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J. Virol. 2009, 83:5726-5734.
32. Poland G.A. Vaccines against avian influenza--a race against time. N. Engl. J. Med. 2006, 354:1411-1413.
33. Prabakaran M., Kolpe A.B., He F., Kwang J. Cross-protective efficacy of bivalent recombinant baculoviral vaccine against heterologous influenza H5N1 challenge. Vaccine 2013, 31:1385-1392.
34. Pushko P., Tumpey T.M., Bu F., Knell J., Robinson R., Smith G. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 2005, 23:5751-5759.
35. Pushko P., Tumpey T.M., Van Hoeven N., Belser J.A., Robinson R., Nathan M., Smith G., Wright D.C., Bright R.A. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine 2007, 25:4283-4290.
36. Qiao C.L., Yu K.Z., Jiang Y.P., Jia Y.Q., Tian G.B., Liu M., Deng G.H., Wang X.R., Meng Q.W., Tang X.Y. Protection of chickens against highly lethal H5N1 and H7N1 avian influenza viruses with a recombinant fowlpox virus co-expressing H5 haemagglutinin and N1 neuraminidase genes. Avian Pathol. 2003, 32:25-32.
37. Quan F.S., Huang C., Compans R.W., Kang S.M. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J. Virol. 2007, 81:3514-3524.
38. Quan F.S., Vunnava A., Compans R.W., Kang S.M. Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PloS One 2010, 5:e9161.
39. Rezaei F., Mirshafiey A., Shahmahmoodi S., Shoja Z., Ghavami N., Mokhtari-Azad T. Influenza virus-like particle containing two different subtypes of hemagglutinin confers protection in mice against lethal challenge with A/PR8 (H1N1) and A/HK (H3N2) viruses. Iran. Red Crescent Med. J. 2013, 15:75-82.
40. Robertson J.S., Engelhardt O.G. Developing vaccines to combat pandemic influenza. Viruses 2010, 2:532-546.
41. Rodriguez-Limas W.A., Sekar K., Tyo K.E. Virus-like particles: the future of microbial factories and cell-free systems as platforms for vaccine development. Curr. Opin. Biotechnol. 2013, 24:1089-1093.
42. Sabarth N., Savidis-Dacho H., Schwendinger M.G., Bruhl P., Portsmouth D., Crowe B.A., Kistner O., Barrett P.N., Kreil T.R., Howard M.K. A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination. Vaccine 2012, 30:5533-5540.
43. Shortridge K.F., Zhou N.N., Guan Y., Gao P., Ito T., Kawaoka Y., Kodihalli S., Krauss S., Markwell D., Murti K.G., Norwood M., Senne D., Sims L., Takada A., Webster R.G. Characterization of avian H5N1 influenza viruses from poultry in Hong Kong. Virology 1998, 252:331-342.
44. Stephenson I., Nicholson K.G., Colegate A., Podda A., Wood J., Ypma E., Zambon M. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003, 21:1687-1693.
45. Suguitan A.L., McAuliffe J., Mills K.L., Jin H., Duke G., Lu B., Luke C.J., Murphy B., Swayne D.E., Kemble G., Subbarao K. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med. 2006, 3:e360.
46. van der Velden M.V., Aichinger G., Pollabauer E.M., Low-Baselli A., Fritsch S., Benamara K., Kistner O., Muller M., Zeitlinger M., Kollaritsch H., Vesikari T., Ehrlich H.J., Barrett P.N. Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming. Vaccine 2012, 30:6127-6135.
47. Watanabe Y., Ibrahim M.S., Ellakany H.F., Kawashita N., Mizuike R., Hiramatsu H., Sriwilaijaroen N., Takagi T., Suzuki Y., Ikuta K. Acquisition of human-type receptor binding specificity by new H5N1 influenza virus sublineages during their emergence in birds in Egypt. PLoS Pathog. 2011, 7:e1002068.